Max Nisen, Columnist

Bristol's Opdivo Dependence Now Looks Dicey

Missteps with its leading cancer drug threaten its lead over Merck.

January 20, 2017 at 7:01 PM UTC

Max Nisen is a healthcare analyst at Bloomberg Intelligence. He previously wrote for Bloomberg Opinion, Quartz and Business Insider.

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

Bristol-Myers Squibb Co. started 2016 as the acknowledged king of immune-boosting cancer drugs. That position has never looked shakier.

Thursday evening, Bristol announced it won't seek accelerated FDA approval for a combination of its leading cancer drug Opdivo and another immune-oncology (IO) drug called Yervoy in treating newly diagnosed lung-cancer patients.